Agios’ Pyrukynd succeeds in key trial of rare red blood cell disorder in kids
Agios’ blood disease treatment Pyrukynd passed a Phase 3 study in PK deficiency in children who do not regularly receive blood transfusions.
The readout arrives …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
